ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Comparison between RECIST v1.1 criteria and the immune-related response criteria

Comparison between RECIST v1.1 criteria and the immune-related response criteria
Category RECIST v1.1 irRC
Measurement of tumor burden Unidimensional Bidimensional
Target lesions Maximum, 5* Maximum, 15 index lesions
New lesion Results in progressive disease at first appearance Up to 10 new visceral lesions and 5 cutaneous lesions may be added to the sum of the products of the two largest perpendicular diameters of all index lesions at any time point
Complete response

Disappearance of all target and nontarget lesions

Nodes must regress to <10 mm short axis

No new lesions

Confirmation required
Partial response

≥30% decrease in tumor burden compared with baseline

Confirmation required

≥50% decrease in tumor burden compared with baseline

Confirmation required
Progressive disease

≥20% + 5 mm absolute increase in tumor burden compared with nadir

Appearance of new lesions or progression of nontarget lesions

≥25% increase in tumor burden compared with nadir or reset baseline

New lesions added to tumor burden

Confirmation required
Stable disease Neither partial response nor progressive disease
RECIST v1.1: Response Evaluation Criteria in Solid Tumors, version 1.1; irRC: immune-related response criteria.
* For the present analysis, the maximum number of target lesions was 10.
¶ ​If an increase in tumor burden is observed at the first scheduled assessment, the baseline is reset to the value observed at the first assessment.
From: Hodi FS, Hwu WJ, Kefford R, et al. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol 2016; 34(13):1510-7. Reprinted with permission. Copyright © 2016 American Society of Clinical Oncology. All rights reserved.
Graphic 107302 Version 5.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟